Opinion|Videos|December 9, 2024
NMOSD Management with New FDA-approved Agents to Reduce Relapse and Hospitalization Rates
Author(s)Michael Levy, MD, PhD
A panelist discusses how neurologists can adapt their NMOSD management strategies based on recent findings about relapse and hospitalization rates, sharing practical advice and clinical experience for optimizing patient outcomes.
Advertisement
Video content above is prompted by the following:
- In your clinical practice, how have you adapted your approach to NMOSD management in light of these recent findings on relapse and hospitalization rates?
- What advice do you have for other neurologists in managing patients with NMOSD and reducing relapse/hospitalization rates?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Brain Games: September 14, 2025
September 14th 2025
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
NeurologyLive® Brain Games: September 14, 2025
3
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
4